Structural Basis for the Development of Avian Virus Capsids That Display Influenza Virus Proteins and Induce Protective Immunity
暂无分享,去创建一个
Elena Pascual | J. Gómez-Blanco | A. Rodriguez-Frandsen | J. Carrascosa | J. Bárcena | J. Castón | A. Nieto | Esther Blanco | José L. Carrascosa | Carlos P. Mata | Josué Gómez-Blanco | Noelia Moreno | Juan Bárcena | Ariel Rodríguez-Frandsen | Amelia Nieto | José R. Castón | E. Blanco | C. Mata | E. Pascual | N. Moreno | Noelia Moreno
[1] E. Varečková,et al. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development , 2010, Virology Journal.
[2] M. Bandehpour,et al. Immunization with M2e-Displaying T7 Bacteriophage Nanoparticles Protects against Influenza A Virus Challenge , 2012, PloS one.
[3] C. Chou,et al. Crystal structure of infectious bursal disease virus VP2 subviral particle at 2.6A resolution: implications in virion assembly and immunogenicity. , 2006, Journal of structural biology.
[4] Martin F. Bachmann,et al. The coming of age of virus-like particle vaccines , 2008, Biological chemistry.
[5] R. Varadarajan,et al. Design of Escherichia coli-Expressed Stalk Domain Immunogens of H1N1 Hemagglutinin That Protect Mice from Lethal Challenge , 2012, Journal of Virology.
[6] B. Trus,et al. Structural polymorphism of the major capsid protein of a double-stranded RNA virus: an amphipathic alpha helix as a molecular switch. , 2005, Structure.
[7] B L Trus,et al. The effects of radiation damage on the structure of frozen hydrated HSV-1 capsids. , 1993, Journal of structural biology.
[8] S. Streatfield,et al. Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development , 2012, Vaccine.
[9] Z. Ku,et al. Chimeric Virus-Like Particle Vaccines Displaying Conserved Enterovirus 71 Epitopes Elicit Protective Neutralizing Antibodies in Mice through Divergent Mechanisms , 2013, Journal of Virology.
[10] A. Jegerlehner,et al. Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity , 2004, The Journal of Immunology.
[11] R. Wagner,et al. Virus-like particles—universal molecular toolboxes , 2007, Current Opinion in Biotechnology.
[12] R. Varadarajan,et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge , 2010, Proceedings of the National Academy of Sciences.
[13] M. Islam,et al. Research on infectious bursal disease--the past, the present and the future. , 2003, Veterinary microbiology.
[14] W. Fiers,et al. Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection , 2011, The Journal of Immunology.
[15] Javier Ortego,et al. Antigen delivery systems for veterinary vaccine development , 2008, Vaccine.
[16] R. Varadarajan,et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection , 2014, Proceedings of the National Academy of Sciences.
[17] B. Chackerian,et al. Virus-like particles: flexible platforms for vaccine development , 2007, Expert review of vaccines.
[18] L. Dixon,et al. Current strategies for subunit and genetic viral veterinary vaccine development. , 2011, Virus research.
[19] B. Delmas,et al. Infectious bursal disease subviral particles displaying the foot-and-mouth disease virus major antigenic site. , 2009, Vaccine.
[20] B. Delmas,et al. Avian adenovirus CELO recombinants expressing VP2 of infectious bursal disease virus induce protection against bursal disease in chickens. , 2004, Vaccine.
[21] Marianne Manchester,et al. Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[22] J. Carrascosa,et al. VP1, the Putative RNA-Dependent RNA Polymerase of Infectious Bursal Disease Virus, Forms Complexes with the Capsid Protein VP3, Leading to Efficient Encapsidation into Virus-Like Particles , 1999, Journal of Virology.
[23] J Bernard Heymann,et al. Bsoft: image processing and molecular modeling for electron microscopy. , 2007, Journal of structural biology.
[24] J. Bárcena,et al. Virus-like particles: The new frontier of vaccines for animal viral infections , 2012, Veterinary Immunology and Immunopathology.
[25] Nicole F Steinmetz,et al. Applications of viral nanoparticles in medicine. , 2011, Current opinion in biotechnology.
[26] G. Rivas,et al. Infectious bursal disease virus is an icosahedral polyploid dsRNA virus , 2009, Proceedings of the National Academy of Sciences.
[27] J. Carrascosa,et al. Different architectures in the assembly of infectious bursal disease virus capsid proteins expressed in insect cells. , 2000, Virology.
[28] D. Ekiert,et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes , 2010, Proceedings of the National Academy of Sciences.
[29] J. Pous,et al. The 2.6-Angstrom Structure of Infectious Bursal Disease Virus-Derived T=1 Particles Reveals New Stabilizing Elements of the Virus Capsid , 2006, Journal of Virology.
[30] W. Kowalczyk,et al. Chimeric Infectious Bursal Disease Virus-Like Particles as Potent Vaccines for Eradication of Established HPV-16 E7–Dependent Tumors , 2012, PloS one.
[31] David A. Anderson,et al. Virus-like particles: Passport to immune recognition , 2006, Methods.
[32] M. Estes,et al. Rotavirus virus-like particles administered mucosally induce protective immunity , 1997, Journal of virology.
[33] Dr Ferdiye Taner,et al. The enzyme-linked immunosorbent assay (ELISA). , 1976, Bulletin of the World Health Organization.
[34] Irina Gutsche,et al. The Birnavirus Crystal Structure Reveals Structural Relationships among Icosahedral Viruses , 2005, Cell.
[35] J. Castón,et al. The C-terminal domain of the pVP2 precursor is essential for the interaction between VP2 and VP3, the capsid polypeptides of infectious bursal disease virus. , 2004, Virology.
[36] E. Mundt,et al. Molecular and Structural Bases for the Antigenicity of VP2 of Infectious Bursal Disease Virus , 2007, Journal of Virology.
[37] S. Elankumaran,et al. A Recombinant Newcastle Disease Virus (NDV) Expressing VP2 Protein of Infectious Bursal Disease Virus (IBDV) Protects against NDV and IBDV , 2004, Journal of Virology.
[38] Jose A. Ruiz-Diaz,et al. The Oligomerization Domain of VP3, the Scaffolding Protein of Infectious Bursal Disease Virus, Plays a Critical Role in Capsid Assembly , 2003, Journal of Virology.
[39] Gira Bhabha,et al. Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.
[40] Marco,et al. Xmipp: An Image Processing Package for Electron Microscopy , 1996, Journal of structural biology.
[41] W. Barclay,et al. Influenza Pandemics , 2011, Advances in experimental medicine and biology.
[42] Martin H. Koldijk,et al. A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.
[43] J. Bárcena,et al. Rabbit hemorrhagic disease virus capsid, a versatile platform for foreign B-cell epitope display inducing protective humoral immune responses , 2016, Scientific Reports.
[44] John Steel,et al. Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.
[45] M. F. Boni,et al. Vaccination and antigenic drift in influenza. , 2008, Vaccine.
[46] A. Rynda-Apple,et al. Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza. , 2013, ACS nano.
[47] M. Bachmann,et al. Exploiting viral properties for the rational design of modern vaccines , 2008, Expert review of vaccines.
[48] J. Bárcena,et al. Design of novel vaccines based on virus-like particles or chimeric virions. , 2013, Sub-cellular biochemistry.
[49] Bernd H. A. Rehm,et al. Bionanotechnology : biological self-assembly and its applications , 2013 .
[50] Walter Fiers,et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.
[51] Noriko Kishida,et al. Cross-Protective Potential of a Novel Monoclonal Antibody Directed against Antigenic Site B of the Hemagglutinin of Influenza A Viruses , 2009, PLoS pathogens.
[52] Martin F. Bachmann,et al. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.
[53] J. Carrascosa,et al. C Terminus of Infectious Bursal Disease Virus Major Capsid Protein VP2 Is Involved in Definition of the T Number for Capsid Assembly , 2001, Journal of Virology.
[54] J. Carrascosa,et al. Electrostatic Interactions between Capsid and Scaffolding Proteins Mediate the Structural Polymorphism of a Double-stranded RNA Virus* , 2009, The Journal of Biological Chemistry.
[55] J. Lepault,et al. The Last C-Terminal Residue of VP3, Glutamic Acid 257, Controls Capsid Assembly of Infectious Bursal Disease Virus , 2004, Journal of Virology.
[56] J. Bárcena,et al. Chimeric calicivirus-like particles elicit specific immune responses in pigs , 2012, Vaccine.
[57] S. Schillberg,et al. Protective Oral Vaccination against Infectious bursal disease virus Using the Major Viral Antigenic Protein VP2 Produced in Pichia pastoris , 2013, PloS one.
[58] J A Lawton,et al. Three-dimensional structural analysis of recombinant rotavirus-like particles with intact and amino-terminal-deleted VP2: implications for the architecture of the VP2 capsid layer , 1997, Journal of virology.
[59] S. Plotkin,et al. History of vaccine development , 2011 .
[60] P. Alves,et al. Virus-like particles in vaccine development , 2010, Expert review of vaccines.
[61] Hiroshi Handa,et al. Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants. , 2014, Virology.
[62] Jean Cohen,et al. Individual Rotavirus-like Particles Containing 120 Molecules of Fluorescent Protein Are Visible in Living Cells* 210 , 2001, The Journal of Biological Chemistry.
[63] J. Dubochet,et al. Cryo-electron microscopy of vitrified specimens , 1988, Quarterly Reviews of Biophysics.
[64] R. Gurny,et al. Recent advances in mucosal immunization using virus-like particles. , 2013, Molecular pharmaceutics.
[65] James R. Swartz,et al. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines , 2013, Proceedings of the National Academy of Sciences.
[66] R. Hai,et al. Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins , 2010, PLoS pathogens.
[67] E. Engvall,et al. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. , 1971, Immunochemistry.